MAPK3 and breast carcinoma: As the activation of ERK1/2 and the p38 MAPK is involved in the proliferation and migration of breast cancer cells (Chen et al., 2009; Zhou et al., 2008), we then assessed the effect of the 2‐FF treatment in the MAPK signaling pathways.